Cas:66655-67-2 3,4-Dihydroquinazolin-2(1H)-one manufacturer & supplier

We serve Chemical Name:3,4-Dihydroquinazolin-2(1H)-one CAS:66655-67-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

3,4-Dihydroquinazolin-2(1H)-one

Chemical Name:3,4-Dihydroquinazolin-2(1H)-one
CAS.NO:66655-67-2
Synonyms:Dihydroquinazolinone;3,4-Dihydroquinazolin-2(1H)-one;1,2,3,4-tetrahydro-quinazolin-2-on;3,4-Dihydro-2(1H)-quinazolinone;2(1H)-Quinazolinone, 3,4-dihydro-
Molecular Formula:C8H8N2O
Molecular Weight:148.162
HS Code:2933990090

Physical and Chemical Properties:
Melting point:241-242ºC
Boiling point:257.2±33.0 °C at 760 mmHg
Density:1.2±0.1 g/cm3
Index of Refraction:1.565
PSA:44.62000
Exact Mass:148.063660
LogP:0.86

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like Dihydroquinazolinone chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2(1H)-Quinazolinone, 3,4-dihydro- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3,4-Dihydroquinazolin-2(1H)-one Use and application,1,2,3,4-tetrahydro-quinazolin-2-on technical grade,usp/ep/jp grade.


Related News: At Day 35 following administration, a bone marrow assessment showed that FT819 persisted and continued to demonstrate tumor clearance, whereas primary CAR T cells, while persisting, were not able to control tumor growth. 3,4-Dihydroquinazolin-2(1H)-one manufacturer Retrogenix��s proprietary cell microarray technology provides a fast, accurate and effective solution for determining the primary target and secondary target (off-target) activities of antibodies, proteins, cell therapies, small molecules and viruses. 3,4-Dihydroquinazolin-2(1H)-one supplier At Day 35 following administration, a bone marrow assessment showed that FT819 persisted and continued to demonstrate tumor clearance, whereas primary CAR T cells, while persisting, were not able to control tumor growth. 3,4-Dihydroquinazolin-2(1H)-one vendor Retrogenix��s proprietary cell microarray technology provides a fast, accurate and effective solution for determining the primary target and secondary target (off-target) activities of antibodies, proteins, cell therapies, small molecules and viruses. 3,4-Dihydroquinazolin-2(1H)-one factory At Day 35 following administration, a bone marrow assessment showed that FT819 persisted and continued to demonstrate tumor clearance, whereas primary CAR T cells, while persisting, were not able to control tumor growth.